Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.36 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.36 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15876540 | 0.84 | PLA2G2C (0.38) | TSHRLPAR3LPAR2PLA2G2CADORA1 | |
| SCHEMBL11327845 | 0.78 | TSHR (0.41) | TSHRLPAR3LPAR2PLA2G2CADORA1 | |
| SCHEMBL22268766 | 0.78 | TSHR (0.41) | TSHRLPAR3LPAR2PLA2G2CADORA1 | |
| SCHEMBL731551 | 0.77 | TSHR (0.40) | TSHRALDH1A1 | |
| SCHEMBL2026655 | 0.77 | LPAR3 (0.52) | TSHRLPAR3LPAR2PLA2G2CADORA1 | |
| SCHEMBL2028447 | 0.77 | LPAR3 (0.52) | TSHRLPAR3LPAR2PLA2G2CADORA1 | |
| SCHEMBL2027305 | 0.77 | LPAR3 (0.52) | TSHRLPAR3LPAR2PLA2G2CADORA1 | |
| SCHEMBL2026917 | 0.77 | LPAR3 (0.52) | TSHRLPAR3LPAR2PLA2G2CADORA1 | |
| SCHEMBL891891 | 0.77 | LPAR3 (0.52) | TSHRLPAR3LPAR2PLA2G2CADORA1 | |
| SCHEMBL2022487 | 0.77 | LPAR3 (0.52) | TSHRLPAR3LPAR2PLA2G2CADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688645-B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2017-06-27 | — | — | US | disclosed |
| US-20160251324-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | SANOFI-AVENTIS (FR) | 2016-09-01 | — | — | US | disclosed |
| US-9309207-B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2016-04-12 | — | — | US | disclosed |
| US-20160024033-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | SANOFI-AVENTIS (FR) | 2016-01-28 | — | — | US | disclosed |
| EP-2300462-B1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | SANOFI SA (FR) | 2014-05-21 | — | — | EP | disclosed |
| US-8722655-B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of tafia | SANOFI (FR) | 2014-05-13 | — | — | US | disclosed |
| US-20140039011-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | SANOFI (FR) | 2014-02-06 | — | — | US | disclosed |
| US-8580777-B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2013-11-12 | — | — | US | disclosed |
| US-20110178130-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| EP-2300462-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | Sanofi-aventis (FR) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009146802-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | SANOFI-AVENTIS (FR) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024033-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | TFPI, TFPI2, SERPINC1 | TSHR 521/4885LPAR3 4801/4885LPAR2 4549/4885 |
| US-20110178130-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | TFPI, TFPI2, SERPINC1 | TSHR 521/4885LPAR3 4801/4885LPAR2 4549/4885 |
| US-20140039011-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | TFPI, TFPI2, SERPINC1 | TSHR 521/4885LPAR3 4801/4885LPAR2 4549/4885 |
| US-20160251324-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | TFPI, TFPI2, SERPINC1 | TSHR 521/4885LPAR3 4801/4885LPAR2 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.